https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3129)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3129)2014-06-01 00:00:002014-06-01 00:00:00Randomized phase II study with dendritic cell (DC) immunotherapy in patients with resected hepatic metastasis of colorectal carcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3062)2014-06-01 00:00:002014-06-01 00:00:00γδ T cells in combination with Newcastle disease virus and dendritic cell therapy as a novel immunotherapeutic approach in treating of advanced lung cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3051)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3051)2014-06-01 00:00:002014-06-01 00:00:00Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)2014-05-31 11:58:292019-07-17 11:58:59Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 7583)2014-05-31 00:00:002019-07-31 11:59:46Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)2014-05-30 00:00:002014-05-30 00:00:00A feasibility and safety study of vaccination with poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic, locally advanced unresectable, or recurrent pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-21 / Expert Rev Anticancer Ther 2014 Jul;14(7):761-32014-05-21 00:00:002019-02-15 08:46:21Dendritic cell immunotherapy for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-16 / Expert Opin Biol Ther 2014 Sep;14(9):1259-702014-05-16 00:00:002019-02-15 08:39:38Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / Cytotherapy 2014 Jul;16(7):946-642014-05-13 00:00:002021-11-15 13:30:25Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-13 / J Immunother Cancer 2014;2:10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-13 / J Immunother Cancer 2014;2:102014-05-13 00:00:002019-02-15 08:46:23Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
